| P50 | author | Daniel H van Raalte | Q89048137 |
| | Michaela Diamant | Q108578052 |
| P2860 | cites work | One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 |
| | Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose | Q28261829 |
| | Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells | Q28473974 |
| | Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 |
| | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 |
| | Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 |
| | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 |
| | The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. | Q33300966 |
| | Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin | Q33804747 |
| | Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 |
| | Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity | Q34109834 |
| | Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 |
| | Islet beta cell failure in type 2 diabetes | Q34698810 |
| | Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets | Q34796756 |
| | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 |
| | The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes | Q35085591 |
| | Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities | Q36321572 |
| | Beta-cell preservation with thiazolidinediones | Q36628951 |
| | Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? | Q36678584 |
| | beta-cell failure in diabetes and preservation by clinical treatment | Q36757992 |
| | Glucolipotoxicity: fuel excess and beta-cell dysfunction. | Q36861036 |
| | Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration | Q36899584 |
| | The role for endoplasmic reticulum stress in diabetes mellitus | Q37019672 |
| | Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins | Q37091579 |
| | Preservation of beta-cell function by targeting beta-cell mass | Q37116279 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes | Q37164521 |
| | Glucolipotoxicity of the pancreatic beta-cell: myth or reality? | Q37269512 |
| | An update on lipotoxic endoplasmic reticulum stress in pancreatic beta-cells | Q37269518 |
| | The sensitivity of pancreatic beta-cells to mitochondrial injuries triggered by lipotoxicity and oxidative stress. | Q37269525 |
| | Transient oxidative stress damages mitochondrial machinery inducing persistent beta-cell dysfunction | Q37358162 |
| | Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. | Q37429250 |
| | Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes | Q38349512 |
| | The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice | Q38363214 |
| | Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6. | Q39959315 |
| | Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities | Q39971422 |
| | Glucagon-like peptide-1 prevents beta cell glucolipotoxicity | Q40565084 |
| | A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes | Q42450726 |
| | Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. | Q42455250 |
| | Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes | Q42469053 |
| | Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes | Q42489695 |
| | Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells | Q42490936 |
| | Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea | Q42505421 |
| | Islets in type 2 diabetes: in honor of Dr. Robert C. Turner | Q43248047 |
| | Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death | Q43596005 |
| | Lipotoxicity in human pancreatic islets and the protective effect of metformin | Q43869352 |
| | Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. | Q43972538 |
| | Acute elevation of NEFA causes hyperinsulinemia without effect on insulin secretion rate in healthy human subjects. | Q44038630 |
| | Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. | Q44328946 |
| | Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes | Q44526985 |
| | Short-term intensive insulin therapy in newly diagnosed type 2 diabetes | Q44865579 |
| | Sulfonylurea induced beta-cell apoptosis in cultured human islets | Q45105959 |
| | Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function | Q45124452 |
| | Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 |
| | Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. | Q45142823 |
| | Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets | Q45218553 |
| | Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice | Q46134848 |
| | Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 |
| | Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes | Q46484235 |
| | Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. | Q46576386 |
| | Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? | Q46774741 |
| | Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus | Q46804042 |
| | Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database | Q46841507 |
| | Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes | Q46953451 |
| | Relationship between beta-cell mass and fasting blood glucose concentration in humans | Q46966775 |
| | Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes | Q47296454 |
| | Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions | Q51015452 |
| | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. | Q51468797 |
| | Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. | Q51478323 |
| | Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. | Q51584824 |
| | Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells. | Q53544467 |
| | The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose | Q57504429 |
| | Elevation of plasma fatty acids by ten-hour intralipid infusion has no effect on basal or glucose-stimulated insulin secretion in normal man | Q73707200 |
| | Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo | Q80838553 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | S37-46 | |
| P577 | publication date | 2011-08-01 | |
| P1433 | published in | Diabetes Research and Clinical Practice | Q15750054 |
| P1476 | title | Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? | |
| P478 | volume | 93 Suppl 1 | |